Development of an RNA-based diagnostic test for MS patient stratification
GeNeuro is a clinical stage pharmaceutical company developing a new approach to the treatment of autoimmune diseases, including multiple sclerosis (MS) and Type 1 Diabetes (T1D) associated with pathogenic proteins expressed by human endogenous retroviruses (HERV), viral genes that account for 8% of human DNA. They developed the antibody GNbAC1 as therapeutic in MS, and a Phase IIb study is currently running.
GeNeuro wanted Biogazelle to develop an RNA-based test to stratify MS patients that will likely benefit from a treatment with GNbAC1. To this end, Biogazelle is currently validating an RT-qPCR based method for accurate measurement of MSRV-Env (Multiple Sclerosis associated retrovirus envelope protein) in peripheral blood mononuclear cells (PBMCs). Pending successful development of the method, Biogazelle will perform the MSRV-Env RNA quantification of the phase 2 and phase 3 clinical trial samples.